Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
S Postel-Vinay, S Aspeslagh, E Lanoy, et al.
British Journal of Cancer
|
April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
C Henon, J-Y Blay, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
T André, C Tournigand, L Mineur, et al.
Oncogene
|
August 13, 2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
S Postel-Vinay, I Bajrami, L Friboulet, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2014
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee
R Califano, M V Karamouzis, S Banerjee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
S Postel-Vinay, Y Boursin, C Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
ESMO Open
|
April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
U M Lauer, A Awada, S Postel-Vinay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration
J Rodon, H Prenen, A Sacher, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
S Postel-Vinay, S Aspeslagh, E Lanoy, et al.
British Journal of Cancer
|
April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
C Henon, J-Y Blay, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
T André, C Tournigand, L Mineur, et al.
Oncogene
|
August 13, 2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
S Postel-Vinay, I Bajrami, L Friboulet, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2014
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee
R Califano, M V Karamouzis, S Banerjee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
S Postel-Vinay, Y Boursin, C Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
ESMO Open
|
April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
U M Lauer, A Awada, S Postel-Vinay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration
J Rodon, H Prenen, A Sacher, et al.
Page
of 4